**Insmed Incorporated to Present at J.P. Morgan Healthcare Conference**

Insmed Incorporated has announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company’s management is scheduled to present at 3:00 p.m. PT (6:00 p.m. ET) on the specified date. A live webcast of the presentation will be available through the investor relations section of Insmed’s website.

In connection with the upcoming presentation, Insmed issued a press release on January 10, 2025. The press release details the information related to the conference participation and is available as Exhibit 99.1 in the filing. Additionally, the slide presentation intended for the conference is attached to the filing as Exhibit 99.2.

It is important to note that the information presented, including the attached exhibits, is not to be considered as “filed” for the Securities Exchange Act of 1934 purposes. This information is not incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act, except if explicitly specified in future filings.

Regarding financial statements and exhibits, Insmed Incorporated filed Exhibit 99.1, which includes the press release issued on January 10, 2025, and Exhibit 99.2, which contains the slide presentation for the J.P. Morgan Healthcare Conference. Additionally, the company submitted Exhibit 104, which is the Cover Page Interactive Data File embedded within the Inline XBRL document.

This move by Insmed is expected to provide valuable insights to stakeholders and investors regarding the company’s standing, strategies, and future prospects in the healthcare sector.

The financial community eagerly anticipates the outcomes and discussions stemming from Insmed’s participation in this prominent conference, which could provide essential momentum and growth opportunities for the company.

The detailed financial statements and exhibits presented signal the company’s commitment to transparency and shareholder engagement, setting a positive tone for its future endeavors.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Insmed’s 8K filing here.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.